17:58:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är verksamma inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg.

Kalender

2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-05-09 Ordinarie utdelning ZEAL 0.00 DKK
2022-04-06 Årsstämma 2022
2022-03-10 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-04-16 Ordinarie utdelning ZEAL 0.00 DKK
2021-04-15 Årsstämma 2021
2021-03-11 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-03 Ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 Årsstämma 2020
2020-03-12 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Kvartalsrapport 2019-Q1
2019-04-05 Ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 Årsstämma 2019
2019-03-07 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-16 Kvartalsrapport 2018-Q1
2018-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 Årsstämma 2018
2018-03-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-17 Kvartalsrapport 2017-Q1
2017-04-06 Ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 Årsstämma 2017
2017-03-15 Bokslutskommuniké 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 Årsstämma 2016
2016-03-16 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-22 Kvartalsrapport 2015-Q1
2015-04-22 Ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 Årsstämma 2015
2015-03-12 Bokslutskommuniké 2014
2014-03-21 Ordinarie utdelning ZEAL 0.00 DKK
2013-04-30 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-26 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 Årsstämma 2012
2011-04-29 Ordinarie utdelning
2021-11-30 18:14:54

Company announcement – No. 73 / 2021

Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021

Copenhagen, DK and Boston, MA, November 30, 2021 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

The Capital Group Companies has notified Zealand about a change of its total holding of voting rights, in accordance with section 38 of the Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Capital Markets Act and financial instruments with similar economic effect according to section 39(2)(2) of the Capital Markets Act, such that it now holds 5.62% of the voting rights of Zealand.

SMALLCAP World Fund, Inc., a fund managed by Capital Group Companies, Inc. has notified Zealand about a change of its total holding of share capital, in accordance with section 38 of the Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Capital Markets Act and financial instruments with similar economic effect according to section 39(2)(2) of the Capital Markets Act, such that it now holds 5.62% of the voting rights of Zealand.

Please see further details in the attached notification forms.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunity for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Zegalogue® and V-Go® are registered trademarks of Zealand Pharma A/S.

Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com 
 
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com